OTLK — Outlook Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $182.18m
- $208.37m
Annual cashflow statement for Outlook Therapeutics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -34.5 | -35.2 | -53.2 | -66.1 | -59 |
| Depreciation | |||||
| Non-Cash Items | 12.1 | 4.17 | 5.73 | 10.9 | 11.2 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13.2 | -1.27 | -7.08 | -1.68 | 4.75 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -32.3 | -31.8 | -54.3 | -56.7 | -43 |
| Capital Expenditures | -0.437 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -0.9 | 0 | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.437 | -0.9 | 0 | — | — |
| Financing Cash Flow Items | 0 | — | -0.008 | -0.6 | -0.824 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39 | 37.2 | 56.2 | 59.6 | 49 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.3 | 4.52 | 1.94 | 2.92 | 6 |